Our Pricing

Understanding Mounjaro Thyroid Cancer Risk & Side Effects

Published on: June 03, 2026

Concerns about mounjaro thyroid cancer risk uk are common among patients considering tirzepatide treatment, particularly after reading the product information leaflet. At Cured Pharmacy, our UK-registered clinical team provides evidence-based guidance to help you understand the actual risk profile, who should avoid Mounjaro, and what the clinical data really shows about thyroid safety in humans.

What Is the Mounjaro Thyroid Cancer Risk UK Warning About?

The thyroid cancer warning on Mounjaro packaging refers specifically to medullary thyroid carcinoma (MTC), a rare type of thyroid cancer that developed in rodent studies when animals were exposed to tirzepatide [1]. This is a regulatory requirement for all GLP-1 receptor agonist medications licensed in the UK, including semaglutide (Wegovy, Ozempic) and liraglutide (Saxenda).

In animal toxicology studies, rats and mice given tirzepatide at doses far exceeding human therapeutic levels developed C-cell tumours in the thyroid gland [1]. However, it's crucial to understand that rodents have fundamentally different thyroid biology compared to humans — they possess significantly higher concentrations of GLP-1 receptors on thyroid C-cells, making them more susceptible to this effect.

The MHRA requires Mounjaro to carry a contraindication for patients with a personal or family history of MTC, or those with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), a genetic condition that increases MTC risk [2]. This is a precautionary measure based on animal data, not confirmed human cases.

Clinical Trial Data: No Confirmed Human Cases of MTC

Across the comprehensive SURPASS clinical trial programme involving over 10,000 participants treated with tirzepatide for up to 72 weeks, there were no confirmed cases of medullary thyroid carcinoma [3]. This includes SURPASS-1 through SURPASS-5, which examined tirzepatide doses ranging from 5mg to 15mg weekly in diverse patient populations.

Similarly, the SURMOUNT-1 trial, which specifically evaluated tirzepatide for weight management in 2,539 adults without diabetes, reported no MTC cases over the 72-week study period, with participants achieving an average weight reduction of up to 22.5% on the highest dose [4]. Independent safety monitoring committees reviewed thyroid-related adverse events throughout all trials and found no signal suggesting increased MTC risk in humans.

Long-term pharmacovigilance data from semaglutide — which has been used in the UK since 2018 — similarly shows no established causal relationship between GLP-1 receptor agonists and thyroid cancer in humans, despite millions of patient-years of exposure worldwide [5].

Why the Rodent Data May Not Apply to Humans

Human thyroid C-cells express GLP-1 receptors at substantially lower levels than rodent C-cells, and the distribution pattern differs significantly [1]. Expert endocrinologists and the European Medicines Agency have noted that the thyroid tumours observed in rodents are likely species-specific and may not be relevant to human risk assessment, though the precautionary contraindication remains in place pending further long-term human data.

Who Should Not Use Mounjaro Due to Thyroid Cancer Risk?

Mounjaro is contraindicated in UK patients with a personal history of medullary thyroid carcinoma, regardless of whether it was treated successfully [2]. If you have previously been diagnosed with MTC, your prescriber will recommend alternative weight management treatments that do not carry this precautionary warning, such as Orlistat or Xenical.

The medication is also contraindicated in patients with a family history of MTC — meaning a first-degree relative (parent, sibling, or child) who has been diagnosed with this specific type of thyroid cancer. This is particularly important because MTC can occur as part of inherited genetic syndromes.

Patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) must not use Mounjaro, as this genetic condition substantially increases the baseline risk of developing MTC [2]. If you have MEN 2 or suspect a family history of endocrine tumours, genetic counselling and screening should be completed before considering any weight loss medication.

Thyroid Cancer Screening Before Starting Mounjaro

Routine thyroid cancer screening is not required before starting Mounjaro in patients without personal or family history of MTC or MEN 2. However, your UK prescriber will take a detailed medical history during your consultation to identify any contraindications. If you notice a lump in your neck, persistent hoarseness, difficulty swallowing, or unexplained neck pain whilst taking Mounjaro, contact your GP immediately for thyroid examination, though these symptoms are far more commonly caused by benign conditions.

Common Mounjaro Side Effects: What to Expect

The most frequently reported side effects of Mounjaro are gastrointestinal and typically occur during dose escalation [3]. In clinical trials, nausea affected approximately 20-30% of participants, particularly in the first 4-8 weeks of treatment, though most cases were mild to moderate and resolved without discontinuation.

Diarrhoea, constipation, vomiting, and abdominal discomfort are also common, especially when increasing from one dose strength to the next [3]. Starting at the lowest 2.5mg dose and gradually titrating upwards every four weeks — as the licensed dosing schedule recommends — significantly reduces the intensity of these effects.

Injection site reactions such as redness, itching, or mild swelling occur in fewer than 5% of patients and are usually transient [4]. Rotating injection sites between the abdomen, thigh, and upper arm as instructed helps minimise localised reactions. Hypoglycaemia (low blood sugar) is uncommon in patients without diabetes but may occur if Mounjaro is used alongside other glucose-lowering medications.

Mounjaro Thyroid Cancer Risk UK Compared to Other Weight Loss Treatments

All GLP-1 receptor agonist medications licensed in the UK — including Wegovy (semaglutide), Saxenda (liraglutide), and Mounjaro (tirzepatide) — carry the same precautionary contraindication regarding MTC based on rodent study data [2][5]. This is not unique to Mounjaro; it reflects a class-wide regulatory requirement applied to all incretin-based therapies.

By contrast, Orlistat-based treatments such as Xenical, Orlos, and Alli work through a completely different mechanism (lipase inhibition) and do not carry any thyroid-related warnings. For patients with a personal or family history of MTC or MEN 2, Orlistat remains a suitable prescription option, though the average weight loss is typically lower than that achieved with GLP-1 receptor agonists [6].

Your UK prescriber at Cured Pharmacy will assess your individual risk factors, medical history, and weight loss goals to recommend the most appropriate treatment. For the majority of patients without thyroid contraindications, the substantial weight loss efficacy of Mounjaro — with an average reduction of 20-22.5% body weight in clinical trials — makes it a highly effective option when combined with lifestyle modification [4].

Switching from Wegovy or Saxenda to Mounjaro

If you are currently taking Wegovy or Saxenda and considering switching to Mounjaro, the thyroid cancer contraindication profile is identical across all three medications. Switching is typically based on efficacy, tolerability, or cost considerations rather than safety differences. Your prescriber will provide guidance on appropriate washout periods and starting doses when transitioning between GLP-1 treatments.

How to Access Mounjaro Safely Through Cured Pharmacy

Mounjaro is a prescription-only medication in the UK and requires a clinical assessment by a UK-registered prescriber before it can be dispensed. At Cured Pharmacy, you'll complete a free online consultation that takes under three minutes, during which our clinical team will review your medical history, current medications, and any contraindications including thyroid-related risk factors.

Our superintendent pharmacist Tarun Kumar (GPhC 2233073) and the UK-registered clinical team ensure that every prescription meets MHRA safety standards and NICE guidance. Pricing is transparent from the outset — Mounjaro starts from £124.99, with the final cost depending on your prescribed dose strength. All orders are dispensed in 100% discreet packaging with next-day delivery options available.

If Mounjaro is not suitable due to thyroid contraindications or other medical factors, our prescribers will recommend alternative treatments from our weight loss range, including Wegovy from £124.99, Saxenda from £135.00, or Orlistat from £135.00. Every patient receives personalised clinical advice tailored to their individual circumstances, with ongoing support available via phone on (+44) 116 4646009.

Scientific References

1. Gier, B., et al. (2012). Glucagon like peptide-1 receptor expression in the human thyroid gland. Journal of Clinical Endocrinology & Metabolism, 97(1), 121–131. https://doi.org/10.1210/jc.2011-2407 [accessed 13 August 2026]
2. Medicines and Healthcare products Regulatory Agency (MHRA). (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Retrieved from https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency [accessed 13 August 2026]
3. Rosenstock, J., et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet, 398(10295), 143–155. https://doi.org/10.1016/S0140-6736(21)01324-6 [accessed 13 August 2026]
4. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
5. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
6. Torgerson, J. S., et al. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155 [accessed 13 August 2026]
7. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
8. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
9. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.